10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo Buys 40,000 Shares

10x Genomics, Inc. (NASDAQ:TXG) Director Alan Mateo acquired 40,000 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the transaction, the director now owns 61,691 shares of the company’s stock, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

10x Genomics Price Performance

Shares of TXG opened at $11.11 on Wednesday. The firm has a market capitalization of $1.36 billion, a PE ratio of -7.31 and a beta of 1.85. The company’s 50-day moving average is $14.16 and its 200-day moving average is $16.95. 10x Genomics, Inc. has a fifty-two week low of $10.63 and a fifty-two week high of $48.42.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 10x Genomics

A number of hedge funds have recently bought and sold shares of the business. FMR LLC increased its position in 10x Genomics by 0.6% during the fourth quarter. FMR LLC now owns 13,454,434 shares of the company’s stock worth $193,206,000 after acquiring an additional 86,455 shares during the period. ARK Investment Management LLC increased its position in 10x Genomics by 11.1% during the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock worth $171,517,000 after acquiring an additional 1,193,712 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in 10x Genomics by 3.7% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock worth $143,907,000 after acquiring an additional 230,145 shares during the period. RA Capital Management L.P. bought a new position in 10x Genomics during the fourth quarter worth about $47,092,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in 10x Genomics by 10.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company’s stock worth $30,394,000 after acquiring an additional 193,588 shares during the period. 84.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Citigroup cut their price objective on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research report on Wednesday, February 19th. Canaccord Genuity Group dropped their price target on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Finally, Leerink Partners cut shares of 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $20.57.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.